Abdullah Al Emran
@emran_geb
Followers
92
Following
406
Media
6
Statuses
97
Research Fellow @FisherLabMGH, Harvard Medical School #Melanoma #Epigenetics #AdaptiveResistance
Boston, MA, USA
Joined January 2010
It has been a fantastic last three years of my research career @CentenaryInst. I am really grateful to my mentors @Peter @JessTiffen, labmates and all other colleagues. I am really excited and looking forward to the next phase of my research career @FisherLabMGH @harvardmed
2
1
13
Delighted to share our latest work which I co-lead with @JessTiffen. Epigenetic inhibitor against BET proteins and antiCTLA-4 synergistically reduce tumor growth which are resistance to anti-PD1. Hope it can make a meaningful impact in clinical settings. @DrHYTseng @JessTiffen.
More great work from my team on epigenetic BET inhibitors. Here we show they combine well with antiCTLA-4 immune checkpoint inhibition (ICI) to combat melanoma with innate resistance to antiPD-1/L1 (frontline) ICI in a mouse model. @DrHYTseng @emran_geb
https://t.co/FhEvXXg3Gz
0
0
6
Great piece of work from my PhD Lab . Yet another strong evidence of epigenetic reprogramming in adaptive resistance of multiple solid tumor models. Congrats to everyone involved in this fascinating project. Happy to be a part of it. @HelmutSchaider@DinoopMenon @Heinz @HaassLab
Hot off the press: Drug Resist Updat, accepted 4th August 2023; doi: https://t.co/epapwck2qb Congrats to Helmut and his team and collaborators - fantastic work! #FrazerInstUQ, @UQDRC, @UQMedicine, @TRI_info, @CUDenver, @UCSF, @otago, @JOAN_RESEARCH, @TheWistar,
0
0
2
Couldn't agree more! A must-read thread..
The Best Scientists 🧵 I have heard a lot about the Best Scientists 🧑🔬 Maybe the best scientists... make impactful discoveries, publish in gilded journals, garner millions in funding, with lots of indirects. And prizes, all the prizes🏆 And everybody respects them. OR…
0
0
3
That's hilarious but harsh truth! Why can't we have both prestige and money??
2
0
6
Happy to share our latest commentary article on "Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma" based on a recent seminal work and our previous works. First from @FisherLabMGH
#Epigenetics #Melanoma
https://t.co/6WQsgIdyiD
jidonline.org
The immunotherapy era has ushered in enormous promise for cancer, largely led by progress in melanoma management. However a significant fraction of melanoma patients suffers early progression or...
1
1
10
Prof Peter Hersey is generally recognised as a pioneer of the #melanoma treatment – #immunotherapy – in Australia. Having first started treating melanoma patients in 1980, he has seen great advances in field but he is not going to stop there. More 👉 https://t.co/9muODpKaKZ
0
2
4
"MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma," a commentary by Charles Adelmann, Inbal Rachmin, & David Fisher https://t.co/m8YQoYEL9U
#JIDJournal #dermscience
0
0
3
Congratulations Australia for winning the maiden T20 World cup title. What a team! What a match! Super proud of you guys... Love and respect for New Zealand. Well played. In the end, cricket wins. #T20WorldCupFinal
https://t.co/O7T7hMto6X
espncricinfo.com
T20 World Cup 2021/22, Australia vs New Zealand Match Report: Williamson's brilliant 85 in vain as New Zealand lose second straight global limited-overs final
0
0
0
Couldn't agree more! 😁👏
0
0
1
Many thanks for promoting our work @CentenaryInst
LATEST NEWS: Researchers from the Centenary Institute have developed a new approach to fighting #melanomas that fail to respond – or are resistant – to standard treatments. More: https://t.co/n0ZQECcP8a
0
0
5
Delighted to share our latest findings- "Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma" Excellent work from @Farzana& @DrHYTseng. My #2 as a co-senior author. @CentenaryInst @Jess @Peter
https://t.co/gs0APBH0pj
jidonline.org
The development of resistance to treatments of melanoma is commonly associated with an upregulation of the MAPK pathway and the development of an undifferentiated state. Previous studies have...
0
0
8
Couldn't agree more! Additionally, It should also be adjusted according to the living cost of some expensive states/cities. It's not a big ask and could be encouraging for the young scientist who wants to pursue their career in academia.
0
0
3
Brilliant piece of work. A must-read for melanoma researchers.
Why do mutations only sometimes cause cancer? In our new @ScienceMagazine paper, we describe a mechanism for this called "oncogenic competence":
0
0
0
Our new findings @biorxivpreprint Happy to share our latest findings on repurposing the existing chemotherapy to induce innate inflammasomes for a potential therapeutic option of BRAF/MAPKi resistant melanoma. @Farzana @DrHYTseng @JessTiffen #PeterHersey @CentenaryInst
Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor-resistant melanoma https://t.co/uWHZvbN9fL
#bioRxiv
0
1
8
The age of epigenetic inhibitors is now and ahead for improving therapeutic efficacy in cancers. A comprehensive review on the role of histone demethylases(erasers) in melanoma other cancers from our lab. Nice work @Gaya19628293 @JessTiffen
Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers https://t.co/uWLvlY4wM8 everything you need to know about lysine demethylases in cancer but didn’t know you needed to know. An excellent review from my PhD student @Gaya19628293 and @emran_geb
0
1
5
Another evidence from our group suggests that epigenetic inhibitors can potentially be an alternative therapeutic option for deadly melanoma.
0
0
1
Our paper is out now in print @JIDJournals. Thanks again to all my colleagues and collaborator. Special thanks to my mentors @JessTiffen, Stuart and Peter. Such a lovely team to work with 🙏 https://t.co/hRyCqbIq07
2
1
11
A fantastic achievement and thoroughly deserved. Many congrats @JessTiffen. Wishing you more success ahead. We are proud of you.
LATEST NEWS: The Centenary Institute's @JessTiffen has been awarded a grant from Cancer Council NSW to investigate a new approach to reverse treatment resistance in #melanoma. https://t.co/6U424bkzZy
@CCNSWResearch
0
0
9